SELLAS Life Sciences (SLS) Other Accumulated Expenses (2011 - 2017)
SELLAS Life Sciences (SLS) posted quarterly Other Accumulated Expenses of $191000.0 for Q4 2017, down 15.86% year-over-year from $227000.0 in Q4 2016, and down 15.86% quarter-over-quarter from $227000.0 in Q4 2016.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Other Accumulated Expenses (2011 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other Accumulated Expenses for 3 consecutive years, with $191000.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Other Accumulated Expenses fell 15.86% year-over-year to $191000.0; the TTM figure through Dec 2017 stood at $191000.0 (down 15.86% YoY), while the FY2017 annual figure was $191000.0, down 15.86% from the prior year.
- Other Accumulated Expenses eased to $191000.0 in Q4 2017 per SLS's latest filing, from $227000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $227000.0 in Q4 2016 and bottomed at $191000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 191,000.00 |
| Dec 31, 2016 | 227,000.00 |
| Dec 31, 2011 | 25,000.00 |